TuHURA Biosciences, Inc. (NASDAQ:HURA) announced on November 4, 2026, that it will present three poster presentations on its Delta Opioid Receptor (DOR) research at the 68th American Society of Hematology Annual Meeting and Exposition, scheduled for December 12-15, 2026, in New Orleans, Louisiana.
Clarivate Plc disclosed via an 8-K press release dated November 4, 2026, that its wholly-owned subsidiary Clarivate Science Holdings Corporation has commenced cash tender offers to purchase up to $500,000,000 aggregate principal amount of its outstanding 3.875% Senior Secured Notes due 2028 and 4.875% …
Cullinan Therapeutics, Inc. filed a Current Report on Form 8-K on November 4, 2026, disclosing updated clinical data from its CLN-049 Phase 1 dose escalation trial in patients with relapsed or refractory acute myeloid leukemia or myelodysplastic syndrome, ahead of a December presentation at …
SelectQuote, Inc. filed a Form 10-Q with the SEC on November 4, 2026, covering the quarterly period ended September 30, 2026, reporting a net loss of $20,301 thousand for the three months ended on that date.
Labcorp Holdings Inc. filed an 8-K on November 4, 2026 under Regulation FD disclosing that Chief Financial Officer Julia Wang will speak at the UBS Global Healthcare Conference on November 10, 2026.
Neostellar Capital Corp. (formerly SuRo Capital Corp.) filed its Form 10-Q for the quarterly period ended September 30, 2026 with the SEC on November 4, 2026, reporting a net asset value of $12.64 per share and a nine-month net change in net assets from …
Circle Internet Group, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the fiscal quarter ended September 30, 2026, and disclosing share counts as of October 29, 2026, alongside detailed descriptions of its digital asset product suite.
Allison Transmission Holdings, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026, with the U.S. Securities and Exchange Commission on November 4, 2026, reporting third-quarter net sales of $1.534 billion and net income of $191 million.
FTC Solar, Inc. filed its quarterly report on Form 10-Q with the SEC on November 4, 2026, covering the period ended September 30, 2026, disclosing revenue growth, a reduced stockholders' deficit, and a significant decline in warrant liability.
UroGen Pharma Ltd. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 4, 2026, reporting a sharp increase in revenue and a narrowed net loss compared to the prior-year quarter.